Pages
- Adcirca®
- Adcirca® FAQ
- Aironite®
- Ambrisentan
- BiPAP / CPAP
- Bosentan
- Calcium Channel Blockers
- Coumadin®
- Digitalis
- Diuretics
- Endothelin Receptor Antagonists
- Epoprostenol for Injection
- Epoprostenol sodium
- Flolan®
- Iloprost
- Inhaled Treprostinil
- INOmax®
- Jantoven®
- Letairis®
- Marfarin®
- Nitric Oxide
- Nitrite
- Other Drugs and Treatments
- Oxygen
- Phosphodiesterase type-5 Inhibitor
- Prostacyclin
- PTE
- Remodulin®
- Revatio®
- Sildenafil Citrate
- Sitaxsentan Sodium
- Tadalafil
- Thelin®
- Tracleer®
- Tracleer® FAQ
- Transplant
- Treprostinil
- Tyvaso®
- Under FDA Review
- Veletri®
- Ventavis®
- Viagra®
- Volibris®
- Warfarin
Under FDA Review
While there is promising research for treatment and reversal of pulmonary hypertension, there are two drugs we are listing as Under FDA Review:
-
Thelin (Sitaxsentan Sodium) (as of November 2010, drug trials in the U.S. were halted. You will find more detailed info under the news section on the Thelin page) - Aironite
Page Reviewed/Edited: January 2011
In The News
- May 11, 2012
- FDA Safety Concerns on new Obesity Drug: Fen Phen Lawsuits
- April 7, 2012
- Selexipag Improves Pulmonary Hypertension in Mid-Stage Trial
- December 16, 2010
- EMA Reviewing Drug Class That Includes Pfizer’s Thelin
.jpg)